Stifel analyst Benjamin Burnett raised the firm’s price target on Mirati Therapeutics to $83 from $77 and keeps a Buy rating on the shares following the company’s Q2 update. The quarterly report included new first-line NSCLC adagrasib data along with initial MRTX1917 data, both of which the firm thinks are “positive” and supportive that adagrasib+pembro will prove to be superior to pembro monotherapy.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on MRTX:
- Mirati Therapeutics 9.7M share Spot Secondary priced at $27.80
- Mirati Therapeutics price target raised to $62 from $56 at Oppenheimer
- Mirati Therapeutics reports Q2 EPS ($3.04), consensus ($3.17)
- Mirati Therapeutics Reports Second Quarter 2023 Financial Results and Recent Corporate Updates
- Mirati Therapeutics announces $250M common stock offering